Antheia, a cutting-edge pharmaceutical ingredient producer, is on a mission to eliminate drug shortages by harnessing advanced biosynthesis and fermentation technology. Through their innovative biomanufacturing platform, Antheia enables swift, efficient, and on-demand production of key starting materials (KSMs) and active pharmaceutical ingredients (APIs) crucial for public health. This adaptable approach caters to the evolving needs of society and enhances global access to vital medicines. Established in 2015, Antheia has evolved into a commercial-stage company, boasting its inaugural product on the market, a robust customer pipeline, and imminent product launches. To delve deeper into Antheia’s revolutionary impact on pharmaceutical supply chains, visit www.antheia.bio.
In a groundbreaking move, Phlow Corp, a prominent American pharmaceutical contract development and manufacturing organization (CDMO), and Antheia have joined forces to reshore the production of essential medicines in the United States. This strategic partnership, initiated in 2024, leverages Antheia’s biosynthesis platform to domestically manufacture key starting materials (KSMs) supporting Phlow’s array of active pharmaceutical ingredients (APIs).
Dr. Eric S. Edwards, CEO and Chairman of Phlow, emphasized the significance of this collaboration in fortifying the domestic supply chain for life-changing medicines that have long depended on imported and often unstable sources for their critical starting materials. The partnership’s primary objective is to develop a sustainable U.S.-based alternative for these materials, safeguarding American patients while advancing the shared mission of bolstering national health security.
The vulnerability of American pharmaceutical supply chains, with nearly 80% of APIs and KSMs originating from overseas, underscores the urgent need for resilience against drug shortages exacerbated by public health crises and global supply chain pressures.
Antheia and Phlow envision a pharmaceutical landscape that harnesses cutting-edge manufacturing technologies like biomanufacturing and continuous flow chemistry to cater to the nation’s dynamic healthcare requirements.
Phlow’s state-of-the-art, flow chemistry-based process facilitates the efficient production of life-saving medications using Regulatory Starting Materials (RSM) cultivated through Antheia’s biosynthesis platform. This comprehensive manufacturing approach offers a holistic solution for onshoring critical drugs pivotal to U.S. health and national security.
Dr. Christina Smolke, CEO and co-founder of Antheia, highlighted the imperative nature of establishing domestic pharmaceutical supply chains and addressing ongoing drug shortages as critical national security imperatives necessitating swift action from both private and public sectors. By integrating Antheia’s biosynthesis and biomanufacturing prowess with Phlow’s advanced domestic infrastructure, the partnership aims to onshore essential medicines and enhance access to crucial drugs for the American populace.
Collaboratively, Phlow and Antheia are paving the way for a new chapter in U.S. pharmaceutical manufacturing, poised to bolster the nation’s economic and national security, public health readiness, and accessibility to essential medications.
As a B Corporation™, Phlow plays a pivotal role in empowering pharmaceutical innovation through advanced development and manufacturing within the United States. With a focus on revolutionizing drug substance development, Phlow collaborates with government and private industry stakeholders to drive forward-thinking approaches supported by scientific expertise, cutting-edge manufacturing capabilities, and technology-driven processes that propel the industry towards a new standard of medicine production. By prioritizing speed to market, waste reduction, and environmentally conscious manufacturing practices, Phlow aims to foster resilient and healthy communities. For further insights, visit phlow-usa.com.
Read more from finance.yahoo.com